New role for NG2/MPG in apoptosis and antitumour drug resistance

Mouldy Sioud
Mouldy Sioud
Chemoresistance represents a major problem in the treatment of many malignancies. Among those working to improve our understanding the mechanisms responsible for this phenomenon is Mouldy Sioud from the Department of Immunology. He is senior author on a recent article on this subject - published online in Oncogene (impact factor 6.6). In this paper - evidence of a new role for NG2/MPG in apoptosis and antitumour drug resisitance is presented.

 

 

 

 


By activating a 3b1 integrin and downstream PI3k/Akt signaling pathway, NG2/MPG was found to promote tumor resistance to antitumour drugs such as doxorubicin, etoposide and carboplatin. Thus, NG2 should represent an effective therapeutic target in several cancer types.

First author on the article - entitled "The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling" - is Martha Chekenya (Department of Biomedicine University of Bergen) and senior authors are Mouldy Sioud and William B. Stallcup (Cancer Research Center, La Jolla, USA).


Links:

Chekenya M, Krakstad C, Svendsen A, Netland IA, Staalesen V, Tysnes BB, Selheim F, Wang J, Sakariassen PO, Sandal T, Lønning PE, Flatmark T, Enger PO, Bjerkvig R, Sioud M, Stallcup WB.
The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.
Oncogene. 2008 May 12.

Download article (in PDF format).

Home page of Mouldy Sioud's group: Molecular Medicine

Department of Immunology

Instiute for Cancer Research

 
Scroll to top